Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EuroPCR 2018 | ORBITA: The Link Between Ischemia and Symptoms Is Still Not Entirely Understood

Invasive physiology tests used in the ORBITA trial could not predict which patients would benefit from angioplasty more than placebo (sham procedure) in terms of the trial’s primary endpoint, improvement in exercise time. These data were presented at EuroPCR 2018 and published simultaneously in Circulation.

ORBITA: Todavía no terminamos de entender la relación entre la isquemia y los síntomasResults encourage debate over the importance of ischemia reduction with angioplasty using fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR), since these values were closely correlated with improvements on stress echocardiography. The lower the baseline FFR or iFR value, the greater the magnitude of benefit following angioplasty as compared with a placebo (sham procedure).

 

In an additional analysis (that was not pre-specified in the original protocol), more patients reported symptom improvement after “true” angioplasty than following a “placebo” procedure. However, neither FFR nor iFR modified this effect. Surprisingly, no relationship was seen between pre-randomization functional test results and changes in symptoms at 6 weeks.


Read also: SCAAR Registry at 10 years: FFR improves decision making in the long term.


Researchers expected intensity and frequency, along exercise time, to vary along the FFR spectrum, but this study showed (within certain technical limitations) that this correlation does not exist. Patients who have very highly ischemic FFR or iFR values did not gain much as regards symptoms after angioplasty, although they did benefit greatly regarding ischemia reduction on stress echo.

 

The overall results of the ORBITA trial were neutral, which limits the ability to do any secondary analyses such as this one.


Read also: SYNTAX III REVOLUTION: Excellent Correlation Between Angiography and Computerized Tomography in Patients with Left Main and Multivessel Disease.


FFR/iFR-guided angioplasty undoubtedly reduces ischemic burden. The problem is that the link between ischemia reduction and symptom relief is not as direct as we expected.

 

Original title: Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease. Physiology-Stratified Analysis of ORBITA.

Reference: Al-Lamee R et al. EuroPCR 2018, simultaneously published in Circulation. 2018: Epub ahead of print.

 

ORBITA-presentación

ORBITA-articulo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...